Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.59+0.34 (+0.34%)
Close on Nov 13, 2026Market cap $6.63BP/E 25.1Yield –
Earnings
Lantheus's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$389.90M
+1.5% on a year earlier
Adjusted fully diluted earnings per share, Q3 FY2026
$1.68
$1.27 a year earlier
Latest guidance
Reaffirmed
May 7, 2026 · 2 items
Quarterly results
Revenue and earnings per share from each of Lantheus's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $389.90M | +1.5% | $0.33 | $1.68 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $388.20M | +2.7% | $1.11 | $1.55 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $377.30M | +1.2% | $1.80 | $1.46 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $406.80M | +4.0% | $0.82 | $1.67 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $384.00M | +1.4% | $0.41 | $1.27 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025before the open | $378.00M | -4.1% | $1.12 | $1.57 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $372.80M | +0.8% | $1.02 | $1.53 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025before the open | $391.10M | +10.5% | -$0.17 | $1.59 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024before the open | $378.70M | +18.4% | $1.79 | $1.70 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024before the open | $394.10M | +22.5% | $0.88 | $1.80 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $370.00M | +23.0% | $1.87 | $1.69 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $354.00M | +34.5% | $1.47 | $1.75 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $319.90M | +33.7% | $1.88 | $1.47 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $321.70M | +43.8% | $1.33 | $1.54 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $300.80M | +44.0% | -$0.04 | $1.47 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $263.20M | +103.1% | -$1.74 | $1.37 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $239.30M | +134.4% | $0.86 | $0.99 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $223.70M | – | $0.61 | $0.89 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 29, 2022before the open | $208.90M | – | $0.61 | $0.97 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $129.60M | – | -$0.59 | $0.25 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $102.10M | – | -$0.20 | $0.08 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Lantheus's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| FY 2026 Revenue | FY2026 | $1.40B – $1.45B | $1.40B – $1.45B | Reaffirmed | May 7, 2026 |
| FY 2026 Adjusted fully diluted EPSnon-GAAP | FY2026 | $5.00 – $5.25 | $5.00 – $5.25 | Reaffirmed | May 7, 2026 |
Guidance vs results
The last range Lantheus gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | FY 2025 Adjusted fully diluted EPS | $5.50 – $5.65 | $6.04Σ4Q | Above range |
| FY2025 | Revenue | $1.49B – $1.51B | $1.54BΣ4Q | Above range |
| Q2 FY2024 | Adjusted Fully Diluted EPS | $1.81 – $1.86 | $1.80 | Below range |
| Q2 FY2024 | Revenue | $380.00M – $390.00M | $394.10M | Above range |
| Q1 FY2024 | Adjusted Fully Diluted EPS | $1.50 – $1.54 | $1.69 | Above range |
| Q1 FY2024 | Revenue | $347.00M – $355.00M | $370.00M | Above range |
| Q3 FY2023 | Adjusted Fully Diluted EPS | $1.30 – $1.35 | $1.47 | Above range |
| Q3 FY2023 | Revenue | $310.00M – $315.00M | $319.90M | Above range |
| Q2 FY2023 | Adjusted Fully Diluted EPS | $1.25 – $1.33 | $1.54 | Above range |
| Q2 FY2023 | Revenue | $300.00M – $310.00M | $321.70M | Above range |
| Q1 FY2023 | Adjusted Fully Diluted EPS | $1.28 – $1.32 | $1.47 | Above range |
| Q1 FY2023 | Revenue | $280.00M – $285.00M | $300.80M | Above range |
| Q4 FY2022 | Adjusted Fully Diluted EPS | $0.95 – $0.98 | $1.37 | Above range |
| Q4 FY2022 | Revenue | $243.00M – $247.00M | $263.20M | Above range |
| Q3 FY2022 | Adjusted Fully Diluted EPS | $0.80 – $0.85 | $0.99 | Above range |
| Q3 FY2022 | Revenue | $220.00M – $230.00M | $239.30M | Above range |
| Q2 FY2022 | Adjusted Fully Diluted EPS | $0.67 – $0.73 | $0.89 | Above range |
| Q2 FY2022 | Revenue | $200.00M – $215.00M | $223.70M | Above range |
| Q1 FY2022 | Adjusted Fully Diluted EPS | $0.45 – $0.50 | $0.97 | Above range |
| Q1 FY2022 | Revenue | $160.00M – $170.00M | $208.90M | Above range |
| Q4 FY2021 | Q4 FY 2021 Adjusted Diluted EPS | $0.15 – $0.18 | $0.25 | Above range |
| Q4 FY2021 | Revenue | $110.00M – $115.00M | $129.60M | Above range |
Guidance history
Every forecast Lantheus put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 7, 2026 | FY 2026 Adjusted fully diluted EPS | FY2026 | $5.00 – $5.25 | Reaffirmed |
| May 7, 2026 | FY 2026 Revenue | FY2026 | $1.40B – $1.45B | Reaffirmed |
| Feb 26, 2026 | FY 2026 Adjusted fully diluted EPS | FY2026 | $5.00 – $5.25 | New |
| Feb 26, 2026 | FY 2026 Revenue | FY2026 | $1.40B – $1.45B | New |
| Nov 6, 2025 | FY 2025 Adjusted fully diluted EPS | FY2025 | $5.50 – $5.65 | New |
| Nov 6, 2025 | FY 2025 Revenue | FY2025 | $1.49B – $1.51B | New |
| Aug 6, 2025 | FY 2025 Adjusted fully diluted EPS | FY2025 | $5.50 – $5.70 | Lowered |
| Aug 6, 2025 | FY 2025 Revenue | FY2025 | $1.48B – $1.51B | Lowered |
| May 7, 2025 | FY 2025 Adjusted fully diluted EPS | FY2025 | $6.60 – $6.70 | Lowered |
| May 7, 2025 | FY 2025 Revenue | FY2025 | $1.55B – $1.59B | Narrowed |
| Feb 26, 2025 | FY 2025 Adjusted Fully Diluted EPS | FY2025 | $7.00 – $7.20 | New |
| Feb 26, 2025 | FY 2025 Revenue | FY2025 | $1.55B – $1.61B | New |
| Nov 6, 2024 | FY 2024 Adjusted Fully Diluted EPS | FY2024 | $6.65 – $6.70 | Raised |
| Nov 6, 2024 | FY 2024 Revenue | FY2024 | $1.51B – $1.52B | Raised |
| Jul 31, 2024 | FY 2024 Adjusted Fully Diluted EPS | FY2024 | $6.60 – $6.70 | Lowered |
| Jul 31, 2024 | FY 2024 Revenue | FY2024 | $1.50B – $1.52B | Raised |
| May 2, 2024 | Adjusted Fully Diluted EPS | Q2 FY2024 | $1.81 – $1.86 | New |
| May 2, 2024 | Adjusted Fully Diluted EPS | FY2024 | $7.00 – $7.20 | Raised |
| May 2, 2024 | Revenue | Q2 FY2024 | $380.00M – $390.00M | New |
| May 2, 2024 | Revenue | FY2024 | $1.50B – $1.52B | New |
| Feb 22, 2024 | Adjusted Fully Diluted EPS | FY2024 | $6.50 – $6.70 | New |
| Feb 22, 2024 | Adjusted Fully Diluted EPS | Q1 FY2024 | $1.50 – $1.54 | New |
| Feb 22, 2024 | Revenue | FY2024 | $1.41B – $1.45B | New |
| Feb 22, 2024 | Revenue | Q1 FY2024 | $347.00M – $355.00M | New |
| Nov 2, 2023 | Adjusted Fully Diluted EPS | FY2023 | $5.80 – $5.85 | Raised |
| Nov 2, 2023 | Revenue | FY2023 | $1.26B – $1.27B | Raised |
| Aug 3, 2023 | Adjusted Fully Diluted EPS | FY2023 | $5.60 – $5.70 | Raised |
| Aug 3, 2023 | Adjusted Fully Diluted EPS | Q3 FY2023 | $1.30 – $1.35 | New |
| Aug 3, 2023 | Revenue | Q3 FY2023 | $310.00M – $315.00M | New |
| Aug 3, 2023 | Revenue | FY2023 | $1.25B – $1.27B | New |
| May 4, 2023 | Adjusted Fully Diluted EPS | FY2023 | $5.45 – $5.70 | Raised |
| May 4, 2023 | Adjusted Fully Diluted EPS | Q2 FY2023 | $1.25 – $1.33 | New |
| May 4, 2023 | Revenue | FY2023 | $1.23B – $1.27B | Raised |
| May 4, 2023 | Revenue | Q2 FY2023 | $300.00M – $310.00M | New |
| Feb 23, 2023 | Adjusted Fully Diluted EPS | FY2023 | $4.95 – $5.10 | New |
| Feb 23, 2023 | Adjusted Fully Diluted EPS | Q1 FY2023 | $1.28 – $1.32 | New |
| Feb 23, 2023 | Revenue | FY2023 | $1.14B – $1.16B | New |
| Feb 23, 2023 | Revenue | Q1 FY2023 | $280.00M – $285.00M | New |
| Nov 3, 2022 | Adjusted Fully Diluted EPS | Q4 FY2022 | $0.95 – $0.98 | New |
| Nov 3, 2022 | Adjusted Fully Diluted EPS | FY2022 | $3.80 – $3.83 | Raised |
| Nov 3, 2022 | Revenue | FY2022 | $915.00M – $919.00M | Raised |
| Nov 3, 2022 | Revenue | Q4 FY2022 | $243.00M – $247.00M | New |
| Aug 4, 2022 | Adjusted Fully Diluted EPS | Q3 FY2022 | $0.80 – $0.85 | New |
| Aug 4, 2022 | Adjusted Fully Diluted EPS | FY2022 | $3.50 – $3.60 | Raised |
| Aug 4, 2022 | Revenue | FY2022 | $885.00M – $905.00M | Raised |
| Aug 4, 2022 | Revenue | Q3 FY2022 | $220.00M – $230.00M | New |
| Apr 29, 2022 | Adjusted Fully Diluted EPS | FY2022 | $2.90 – $3.15 | Raised |
| Apr 29, 2022 | Adjusted Fully Diluted EPS | Q2 FY2022 | $0.67 – $0.73 | New |
| Apr 29, 2022 | Revenue | FY2022 | $800.00M – $835.00M | New |
| Apr 29, 2022 | Revenue | Q2 FY2022 | $200.00M – $215.00M | New |
| Feb 24, 2022 | Adjusted Fully Diluted EPS | Q1 FY2022 | $0.45 – $0.50 | New |
| Feb 24, 2022 | Adjusted Fully Diluted EPS | FY2022 | $1.95 – $2.05 | New |
| Feb 24, 2022 | Revenue | FY2022 | $685.00M – $710.00M | New |
| Feb 24, 2022 | Revenue | Q1 FY2022 | $160.00M – $170.00M | New |
| Nov 4, 2021 | Q4 FY 2021 Adjusted Diluted EPS | Q4 FY2021 | $0.15 – $0.18 | New |
| Nov 4, 2021 | FY 2021 Adjusted Diluted EPS | FY2021 | $0.40 – $0.43 | New |
| Nov 4, 2021 | Q4 FY 2021 Revenue | Q4 FY2021 | $110.00M – $115.00M | New |
| Nov 4, 2021 | FY 2021 Revenue | FY2021 | $405.00M – $410.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Lantheus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?